Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fabric.AI, Inc.WPCS · Entity 7732 | Director | March 30, 2017 | April 06, 2017 |
| Neurotrope, Inc.NTRP · Entity 144906 | Director | December 01, 2020 | December 03, 2020 |
| PharmaCyte Biotech, Inc.PMCB · Entity 8256 | Director | March 31, 2026 | July 17, 2026 |
| TAO Synergies Inc.TAOX · Entity 7482 | Director | August 06, 2025 | October 17, 2025 |
| TaoWeave, Inc.OBLG · Entity 8246 | Director | November 14, 2025 | November 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fabric.AI, Inc.
Report date March 30, 2017 · Filed April 06, 2017
This filing explicitly reported no securities owned.
Neurotrope, Inc.
Report date December 01, 2020 · Filed December 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 1
1 source rowRow 1 · 2020-12-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-01 · Disposition to issuer · Disposed 7,813 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-01 · Disposition to issuer · Disposed 1,562 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.06 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-01 · Disposition to issuer · Disposed 80,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.
F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
PharmaCyte Biotech, Inc.
Report date March 31, 2026 · Filed July 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-31 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-03-31 · Other · Acquired 0 · Balance 0 F1: The reported grant was made in error and has been cancelled. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported grant was made in error and has been cancelled.
TAO Synergies Inc.
Report date August 06, 2025 · Filed October 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.38 · Expires 2035-07-14 | Direct | 10,000 |
Reported balance
After 2025-08-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-08-06 · Grant · Acquired 10,000 · Balance 10,000 F1: The option grant was approved by a committee of TAO Synergies Inc.'s (the "Issuer") board of directors on July 14, 2025 subject to shareholder approval of an amendment to the Issuer's 2020 Equity Incentive Plan (the "Plan") to increase the number of shares authorized for issuance of awards under the Plan. The Issuer received shareholder approval of the amendment to the Plan on August 6, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by a committee of TAO Synergies Inc.'s (the "Issuer") board of directors on July 14, 2025 subject to shareholder approval of an amendment to the Issuer's 2020 Equity Incentive Plan (the "Plan") to increase the number of shares authorized for issuance of awards under the Plan. The Issuer received shareholder approval of the amendment to the Plan on August 6, 2025.
TaoWeave, Inc.
Report date November 14, 2025 · Filed November 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2025-11-14 transaction · row 1
1 source rowRow 1 · 2025-11-14 · Purchase · Acquired 10,000 · Balance 25,000 |
| Common WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.41 · Expires 2028-10-01 | Direct | 61,351 |
Reported balance
Holding disclosure · report date 2025-11-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 61,351 F1: Represents the issuance of warrants to purchase common stock of the issuer. The initial exercise date of the warrants was six months from the grant date, and the warrants expire on the fifth anniversary of the initial exercise date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the issuance of warrants to purchase common stock of the issuer. The initial exercise date of the warrants was six months from the grant date, and the warrants expire on the fifth anniversary of the initial exercise date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 22:17 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 119,170 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001683168-26-002631 · ownership.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,170 Underlying: Common Stock · 119,170 shares Expires 2036-03-30 F1 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter. Read SEC document |
| March 31, 2026 Filed Jul 17, 2026 21:00 UTC Amendment | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | OtherStock Option (Right to Buy) · Derivative | 0 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-26-005620 · ownership.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · security: The reported grant was made in error and has been cancelled. F1 · derivative.exercise_price: The reported grant was made in error and has been cancelled. F1 · date: The reported grant was made in error and has been cancelled. F1 · kind: The reported grant was made in error and has been cancelled. F1 · shares: The reported grant was made in error and has been cancelled. F1 · price: The reported grant was made in error and has been cancelled. F1 · derivative.exercise_date: The reported grant was made in error and has been cancelled. F1 · derivative.expiration_date: The reported grant was made in error and has been cancelled. F1 · derivative.underlying: The reported grant was made in error and has been cancelled. F1 · derivative.underlying_shares: The reported grant was made in error and has been cancelled. F1 · balance_after: The reported grant was made in error and has been cancelled. Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 22:43 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | PurchaseCommon Stock | 20,000 | $0.84 | $16,872.00 |
DisclosureSEC source: 0001683168-26-000147 · ownership.xml · nonDerivative · entry 3 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,500 Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 22:43 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | PurchaseCommon Stock | 20,000 | $0.79 | $15,808.00 |
DisclosureSEC source: 0001683168-26-000147 · ownership.xml · nonDerivative · entry 2 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,500 Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 22:43 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | PurchaseCommon Stock | 20,000 | $0.78 | $15,552.00 |
DisclosureSEC source: 0001683168-26-000147 · ownership.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,500 Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:07 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | Tax withholdingCommon Stock | 67,500 | $1.02 | $68,850.00 |
DisclosureSEC source: 0001683168-25-009113 · ownership.xml · nonDerivative · entry 2 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,500 F1 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 22:07 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-009113 · ownership.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 18:11 UTC | TaoWeave, Inc. OBLG · Entity 8246 | PurchaseCOMMON STOCK | 10,000 | $1.91 | $19,100.00 |
DisclosureSEC source: 0001437749-25-035345 · rdgdoc.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| September 17, 2025 Filed Sep 17, 2025 20:01 UTC | TaoWeave, Inc. OBLG · Entity 8246 | PurchaseCOMMON STOCK | 5,000 | $2.70 | $13,475.50 |
DisclosureSEC source: 0001437749-25-029280 · rdgdoc.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| September 16, 2025 Filed Sep 16, 2025 19:59 UTC | TaoWeave, Inc. OBLG · Entity 8246 | PurchaseCOMMON STOCK | 10,000 | $2.73 | $27,321.00 |
DisclosureSEC source: 0001437749-25-029161 · rdgdoc.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| August 06, 2025 Filed Oct 17, 2025 21:11 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001104659-25-100460 · tm2529010-3_4seq1.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-07-14 F1 · date: The option grant was approved by a committee of TAO Synergies Inc.'s (the "Issuer") board of directors on July 14, 2025 subject to shareholder approval of an amendment to the Issuer's 2020 Equity Incentive Plan (the "Plan") to increase the number of shares authorized for issuance of awards under the Plan. The Issuer received shareholder approval of the amendment to the Plan on August 6, 2025. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:05 UTC | TAO Synergies Inc. TAOX · Entity 7482 | Tax withholdingCommon Stock, par value $0.0001 per share | 8,630 | $7.85 | $67,745.50 |
DisclosureSEC source: 0001104659-25-065278 · tm2519649-3_4seq1.xml · nonDerivative · entry 2 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,035 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:05 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 21,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-065278 · tm2519649-3_4seq1.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,665 F1 · balance_after: Includes (i) 21,575 restricted stock units granted on June 30, 2025, under the Issuer's 2020 Equity Incentive Plan which vested immediately upon issuance and (ii) 1,090 shares of common stock. Read SEC document |
| April 25, 2025 Filed Dec 12, 2025 22:07 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 63,233 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001683168-25-009113 · ownership.xml · derivative · entry 3 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,233 Underlying: Common Stock · 63,233 shares Expires 2035-04-24 F2 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter. This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 21:00 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001104659-25-032682 · tm2511539-2_4seq1.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock, par value $0.0001 per share · 800 shares Expires 2035-04-03 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 3, 2025. Read SEC document |
| April 30, 2024 Filed Jul 17, 2024 20:58 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 38,009 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001683168-24-004916 · ownership.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,009 Underlying: Common Stock · 38,009 shares Expires 2034-04-30 F1 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter. This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 20:06 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001104659-24-045799 · tm2411531-2_4seq1.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock, par value $0.0001 per share · 800 shares Expires 2034-04-08 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 8, 2024. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:01 UTC | PharmaCyte Biotech, Inc. PMCB · Entity 8256 | GrantStock Option (Right to Buy) · Derivative | 61,248 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001683168-23-008430 · ownership.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,248 Underlying: Common Stock · 61,248 shares Expires 2033-11-20 Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:18 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001104659-23-040203 · tm2311075-4_4seq1.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 per share · 20,000 shares Expires 2033-03-29 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following March 29, 2023. Read SEC document |
| December 16, 2022 Filed Dec 21, 2022 01:01 UTC | TAO Synergies Inc. SNPX · Entity 7482 | SaleCommon Stock, par value $0.0001 per share | 20,250 | $1.17 | $23,730.98 |
DisclosureSEC source: 0001104659-22-128769 · tm2233089-4_4seq1.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 F1 · shares: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:01 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 72,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-22-119873 · tm2230820-1_4seq1.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock, par value $0.0001 per share · 72,000 shares Expires 2032-11-15 F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 21:01 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001104659-22-043273 · tm2212026-2_4seq1.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock, par value $0.0001 per share · 1,500 shares Expires 2032-04-05 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 5, 2022. Read SEC document |
| April 05, 2022 Filed Jun 23, 2022 22:00 UTC Amendment | TAO Synergies Inc. SNPX · Entity 7482 | OtherStock Option (Right to Buy) · Derivative | 0 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-073971 · tm2219110-2_4aseq1.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · Not disclosed shares Expires not disclosed F1 · security: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.exercise_price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · kind: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · price: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.exercise_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.expiration_date: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.underlying: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · derivative.underlying_shares: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · balance_after: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. F1 · ownership.direct: This filing is deemed to amend the Form 4, which was filed on April 6, 2022, on behalf of Mr. Schechter, showing a grant of 1,500 stock options to purchase shares of common stock of Synaptogenix, Inc. on April 5, 2022, to reflect that such grant was null and void ab initio. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 22:07 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-092718 · tm2122331-5_4seq1.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 F1 · balance_after: Includes 45,000 restricted stock units granted on July 13, 2021 (the "Grant Date") under the Issuer's 2020 Equity Incentive Plan which will vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one year anniversary of the Grant Date. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:39 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 80,000 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0001104659-20-132148 · tm2037705d1_4.xml · derivative · entry 7 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:39 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $0.82 | Not disclosed |
DisclosureSEC source: 0001104659-20-132148 · tm2037705d1_4.xml · derivative · entry 6 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:39 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $4.06 | Not disclosed |
DisclosureSEC source: 0001104659-20-132148 · tm2037705d1_4.xml · derivative · entry 5 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:39 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0001104659-20-132148 · tm2037705d1_4.xml · derivative · entry 4 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:39 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 1,562 | Not disclosed Strike: $4.44 | Not disclosed |
DisclosureSEC source: 0001104659-20-132148 · tm2037705d1_4.xml · derivative · entry 3 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,562 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:39 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerStock Option (right to buy) · Derivative | 7,813 | Not disclosed Strike: $4.44 | Not disclosed |
DisclosureSEC source: 0001104659-20-132148 · tm2037705d1_4.xml · derivative · entry 2 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,813 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:39 UTC | Neurotrope, Inc. NTRP · Entity 144906 | Disposition to issuerCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-132148 · tm2037705d1_4.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. Read SEC document |
| November 24, 2020 Filed Nov 27, 2020 17:06 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001104659-20-130069 · tm2037145d1_4.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-11-24 F1 · derivative.exercise_date: The shares will immediately vest and become exercisable subject to and upon consummation of (1) the merger of PM Merger Sub 1, LLC with and into Metuchen Pharmaceuticals, LLC ("Metuchen"), with Metuchen surviving as a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. ("Petros") and (2) the merger of PN Merger Sub 2, Inc. with and into Neurotrope, Inc. ("Neurotrope"), with Neurotrope surviving as a wholly-owned subsidiary of Petros (together, the "Mergers"). F2 · derivative.expiration_date: In the event the reporting person departs from the board of directors following the consummation of the Mergers, the options shall expire on the date that is one year from the date of the consummation of the Mergers. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 09:01 UTC | Neurotrope, Inc. NTRP · Entity 144906 | PurchaseCommon Stock | 25,000 | $0.98 | $24,442.50 |
DisclosureSEC source: 0001104659-20-120279 · tm2034740d1_form4.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Read SEC document |
| October 22, 2020 Filed Oct 26, 2020 09:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | PurchaseCommon Stock | 25,000 | $1.10 | $27,500.00 |
DisclosureSEC source: 0001104659-20-118010 · tm2034177d1_4.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 09:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | PurchaseCommon Stock | 22,988 | $1.10 | $25,286.80 |
DisclosureSEC source: 0001104659-20-117012 · tm2034030d1_4.xml · nonDerivative · entry 2 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 09:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | PurchaseCommon Stock | 2,012 | $1.10 | $2,213.20 |
DisclosureSEC source: 0001104659-20-117012 · tm2034030d1_4.xml · nonDerivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,012 Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 18:01 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001104659-20-037866 · tm2013506d4_4.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-03-20 F1 · security: The stock option award was made in connection with the Issuer's annual equity grants to non-employee directors pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. Read SEC document |
| March 15, 2019 Filed Apr 15, 2019 17:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001144204-19-019711 · tv518874_form4.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-03-15 F1 · security: The stock option award was made in connection with the Issuer's annual equity grants to non-employee directors pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 18:04 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001144204-19-002690 · tv511531_4.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 17:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 1,562 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001144204-18-064946 · tv509204_4.xml · derivative · entry 2 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562 Underlying: Common Stock · 1,562 shares Expires 2028-12-13 F2 · shares: These securities were issued in connection with the Reporting Person's service on the Audit Committee of the Issuer's board of directors. F3 · derivative.exercise_date: The stock options shall vest in equal daily installments over a three-year period beginning on the date of grant. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 17:00 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 7,813 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001144204-18-064946 · tv509204_4.xml · derivative · entry 1 SCHECHTER JONATHAN · CIK 0001619259 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,813 Underlying: Common Stock · 7,813 shares Expires 2028-12-13 F1 · shares: These securities were issued in connection with the Reporting Person's appointment as a non-employee director to the Issuer's board of directors. F3 · derivative.exercise_date: The stock options shall vest in equal daily installments over a three-year period beginning on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.